Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Trial Profile

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Dacarbazine
  • Indications Leiomyosarcoma; Liposarcoma; Myxoid liposarcoma; Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd; Eisai Inc
  • Most Recent Events

    • 01 Apr 2021 Results of an exploratory molecular analysis published in the Clinical Cancer Research
    • 24 Jun 2020 Results assessing the molecular profile of LMS tumors from North American study sites assessing to identify potential predictive molecular factors for treatment with eribulin, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
    • 08 May 2019 Results of a sub-group analysis assessing eribulin versus dacarbazine in patients with leiomyosarcoma (n=309) published in the British Journal of Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top